The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Leif Groop

Leif Groop

Principal investigator

Leif Groop

IL6 gene promoter polymorphisms and type 2 diabetes - Joint analysis of individual participants' data from 21 studies


  • Cornelia Huth
  • Iris M. Heid
  • Caren Vollmert
  • Christian Gieger
  • Harald Grallert
  • Johanna K. Wolford
  • Birgit Langer
  • Barbara Thorand
  • Norman Klopp
  • Yasmin H. Hamid
  • Oluf Pedersen
  • Torben Hansen
  • Valeriya Lyssenko
  • Leif Groop
  • Christa Meisinger
  • Angela Doring
  • Hannelore Lowel
  • Wolfgang Lieb
  • Christian Hengstenberg
  • Wolfgang Rathmann
  • Stephan Martin
  • Jeffrey W. Stephens
  • Helen Ireland
  • Hugh Mather
  • George J. Miller
  • Heather M. Stringham
  • Michael Boehnke
  • Jaakko Tuomilehto
  • Heiner Boeing
  • Matthias Mohlig
  • Joachim Spranger
  • Andreas Pfeiffer
  • Ingrid Wernstedt
  • Anders Niklason
  • Abel Lopez-Bermejo
  • Jose-Manuel Fernandez-Real
  • Robert L. Hanson
  • Luis Gallart
  • Joan Vendrell
  • Anastasia Tsiavou
  • Erifili Hatziagelaki
  • Steve E. Humphries
  • H. -Erich Wichmann
  • Christian Herder
  • Thomas Illig

Summary, in English

Several lines of evidence indicate a causal role of the cytokine interleukin (IL)-6 in the development of type 2 diabetes in humans. Two common polymorphisms in the promoter of the IL-6 encoding gene IL6, -174G > C (rs1800795) and -573G > C (rs1800796), have been investigated for association with type 2 diabetes in numerous studies but with results that have been largely equivocal. To clarify the relationship between the two IL6 variants and type 2 diabetes, we analyzed individual data on > 20,000 participants from 21 published and unpublished studies. Collected data represent eight different countries, making this the largest association analysis for type 2 diabetes reported to date. The GC and CC genotypes of IL6 -174G > C were associated with a decreased risk of type 2 diabetes (odds ratio 0.91, P = 0.037), corresponding to a risk modification of nearly 9%. No evidence for association was found between IL6 -573G > C and type 2 diabetes. The observed association of the IL6 -174 C-allele with a reduced risk of type 2 diabetes provides further evidence for the hypothesis that immune mediators are causally related to type 2 diabetes; however, because the association is borderline significant, additional data are still needed to confirm this finding.


  • Genomics, Diabetes and Endocrinology

Publishing year












Document type

Journal article


American Diabetes Association Inc.


  • Endocrinology and Diabetes



Research group

  • Genomics, Diabetes and Endocrinology


  • ISSN: 1939-327X